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Prevalence and Predictors of Off-Label Use of
Cardiac Resynchronization Therapy in Patients
Enrolled in the National Cardiovascular Data
Registry Implantable Cardiac-Defibrillator Registry
Adam S. Fein, MD,* Yongfei Wang, MS,† Jeptha P. Curtis, MD,†
Frederick A. Masoudi, MD, MSPH,‡ Paul D. Varosy, MD,§ Matthew R. Reynolds, MD, MSC,*
on behalf of the National Cardiovascular Data Registry
Boston, Massachusetts; New Haven, Connecticut; and Denver, Colorado
Objectives The purpose of the study was to define the extent and nature of cardiac resynchronization therapy (CRT) device
usage outside consensus guidelines using national data.
Background Recent literature has shown that the application of CRT in clinical practice frequently does not adhere to
evidence-based consensus guidelines. Factors underlying these practices have not been fully explored.
Methods From the National Cardiovascular Data Registry’s Implantable Cardiac-Defibrillator Registry, we defined a cohort
of 45,392 cardiac resynchronization therapy-defibrillator (CRT-D) implants between January 2006 and June
2008 with a primary prevention indication. We defined “off-label” implants as those in which the ejection frac-
tion was 35%, the New York Heart Association functional class was below III, or the QRS interval duration was
120 ms in the absence of a documented need for ventricular pacing. The relationships between patient, im-
planting physician, and hospital characteristics with off-label use were explored with multivariable hierarchical
logistic regression models.
Results Overall, 23.7% of devices were placed without meeting all 3 implant criteria, most often due to New York Heart
Association functional class below III (13.1% of implants) or QRS interval duration 120 ms (12.0%). Atrial fi-
brillation/flutter, previous percutaneous coronary intervention, and the performance of an electrophysiology
study before implant were independently associated with increased odds of off-label use, whereas diabetes mel-
litus, increasing age, and female sex were associated with decreased odds. Physician training and insurance
payer were weakly associated with the likelihood of off-label use.
Conclusions Nearly 1 in 4 patients receiving CRT devices in the study time frame did not meet guideline-based indications.
Given the evolving evidence base supporting the use of CRT, these practices require careful scrutiny. (J Am
Coll Cardiol 2010;56:766–73) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.025s
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ccepted May 13, 2010.urvival (1–4). In 2005, the American College of Cardiol-
gy/American Heart Association strongly endorsed CRT
or patients with a left ventricular ejection fraction (LVEF)
35%, QRS interval duration 120 ms, and New York
eart Association (NYHA) functional class III or IV heart
ailure despite optimal drug therapy (Class I recommenda-
ion; Level of Evidence: A) (5). These recommendations
ave subsequently been further strengthened and refined
6,7). Adoption of CRT has been rapid: cardiac resynchro-
ization therapy-defibrillator (CRT-D) systems recently
omprised 40% of all implantable cardiac-defibrillator
ICD) implants in the U.S. (8).
While the question of whether patients outside these
nitially approved treatment criteria could still derive benefit
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August 31, 2010:766–73 Off-Label Use of CRT Defibrillatorsrom CRT is a source of continued investigation, these
uidelines remain the standard of care (9). However, recent
tudies suggest that the application of CRT in clinical
ractice frequently does not adhere to evidence-based con-
ensus guideline recommendations (10,11). To further un-
erstand current CRT utilization patterns, we sought to
efine the extent and nature of CRT implantation outside
onsensus guidelines using data from the National Cardio-
ascular Data Registry (NCDR) ICD Registry, and inves-
igate the patient- and provider-related factors associated
ith “off-label” device usage.
ethods
ata source. Analyses in this study used data from the
CDR’s ICD Registry, a Centers for Medicare and Medicaid
ervices mandated national, ongoing, prospective, observa-
ional database developed in collaboration with American
ollege of Cardiology Foundation and the Heart Rhythm
ociety. In January 2005, a Centers for Medicare and Medicaid
ervices national coverage decision stipulated that all Medicare
eneficiaries receiving an ICD for primary prevention of
udden cardiac death be enrolled in a national registry. The
CDR’s ICD Registry was established later in 2005 and
ecame the sole repository for data collection in April 2006.
lthough hospitals are not required to submit data for non-
edicare patients, 75% of hospitals participating in the
egistry have entered data on all ICD implantations regardless
f indication or insurance (12). Clinical, demographic, and
rocedural information for each implant procedure are col-
ected on 130 standardized data elements. Data are submit-
ed by participating hospitals on a quarterly basis using Amer-
can College of Cardiology-certified software. Data analysis is
erformed by an independent academic analytic center.
tudy population. The population of interest was ICD
ith CRT (CRT-D) device implantations in ICD Registry
atients for the primary prevention of sudden cardiac death
etween January 2006 and June 2008. From the 105,543
RT-D implanted devices enrolled from 1,300 hospitals in
he ICD Registry, we excluded devices placed in patients
ho had a pacemaker, previous ICD, or any clinical
haracteristic that would have warranted an ICD for sec-
ndary prevention (history of cardiac arrest, sustained ven-
ricular tachycardia, or syncope), leaving 45,776 implants.
n additional 384 patients were excluded because of incom-
lete data on the key variables used to define the use of
ff-label devices (QRS, ejection fraction [EF], and NYHA
unctional class). A study cohort of 45,392 implants was
dentified for analysis, as shown in Figure 1.
utcomes measured. The primary outcome measure was
he proportion of patients who underwent CRT device
lacement without meeting the criteria of consensus guide-
ines that were current during the study period (5,7). We
efined such off-label usage as device implantation in
atients with any of the following: 1) documented LVEF u35%; 2) NYHA functional class
elow III; or 3) a QRS interval
uration 120 ms without a need
or ventricular pacing. Patients
ith atrial fibrillation (AF) who
therwise met standard CRT im-
lant criteria were considered “on
abel” (Class IIa recommendation).
urther, as contemporaneous con-
ensus guidelines considered CRT
easonable (Class IIa) in patients
ith a QRS interval duration of
120 ms but expected or actual
requent reliance on ventricular
acing (7), we considered patients
ith a QRS 120 to still be on
abel when there was documenta-
ion of a significant atrioventricu-
ar (AV) conduction abnormality (second- or third-degree AV
lock or PR interval 300 ms). Although guidelines also
dvise “optimal medical therapy” as an additional pre-
ondition for CRT implantation, we did not believe that this
riterion was practical to apply in the registry setting. A
econdary analysis was performed from within the off-label
roup to determine the prevalence of more extreme deviations
rom guideline recommendations, identifying the frequency of
RT implantation in patients with NYHA functional class I,
QRS interval 100 ms, or LVEF 35%.
tatistical analysis. The relationship of various patient-,
hysician-, and hospital-related factors with off-label
RT-D implantation was explored using univariate and
ultivariable analyses. First, the cohort was divided into off-
nd on-label groups as described above. These groups were
ompared using chi-square tests for categorical variables and
tests for continuous variables. Variables in this analysis
ncluded patient demographics (age, sex, race, insurance
ype); reason for hospitalization; patient comorbidities and
ardiac risk factors; selected baseline electrocardiographic
nd laboratory findings; physician training; and hospital
haracteristics (e.g., ownership, size, teaching status, and
ocation).
The independent association of key variables of interest
age, sex, race, insurance status, physician training) as well as
ther variables associated with the use of off-label devices in
nivariate comparisons was assessed using hierarchical lo-
istic regression modeling for the use of off-label devices, to
ccount for the clustering of patients among hospitals. A
ackward stepwise selection algorithm was used in the
odel, and only variables with a p value 0.05 were kept.
ariables used to define off- versus on-label implantation
ere not considered in the models.
We calculated the proportion of CRT-D implants con-
idered off-label for each of the 10 calendar quarters during
he study period and assessed the possible temporal trends
Abbreviations
and Acronyms
AF  atrial fibrillation
AV  atrioventricular
CRT  cardiac
resynchronization therapy
EF  ejection fraction
EP  electrophysiology
ICD  implantable
cardiac-defibrillator
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
PCI  percutaneous
coronary interventionsing the Cochran-Armitage trend test.
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Off-Label Use of CRT Defibrillators August 31, 2010:766–73We also hypothesized that patients who deviated with
espect to 1 implant criterion would have more abnormal
alues of the other criteria than on-label patients (e.g., that
mong CRT recipients with an LVEF35%, average QRS
uration would be greater than among those with an LVEF
35%; or that for CRT-D recipients with a QRS duration
f120 ms, mean LVEF would be lower than among those
ith a QRS duration 120 ms). To assess this hypothesis,
e stratified the study cohort by each individual implant
riterion (NYHA functional class, QRS duration, and EF)
nd qualitatively compared the other implant criteria ac-
ording to these groupings.
Statistical analyses were performed using SAS version 9.1
CRT-D Implantations between 1/06 to 6/08
                             (N = 105,543)
Exclusions
Pacemaker (N = 14,448)
or Previous ICD (N=23,479)
ICD for Secondary Prevention (N=14,431)
or history of cardiac arrest (N=954)
Sustained VT (N=1,035),
or syncope (N=5,420)
or QRS/EF/NYHA Class unknown (N=384)
CRT-D Implantations Identified as Study Cohort
(N=45,392)
Off-Label CRT-D
Implantation Group
EF > 35% (N = 582)
NYHA Class < III
(N=5,959)
QRS duration <120ms
without a need for ventricular
pacing (N=5,432)
34,655 CRT-D implantations
for Primary Prevention in
Adherence with ACC/AHA
Guidelines
Figure 1 Derivation of Study Cohort
Flow diagram showing the derivation of the study cohort of patients receiving
first-time cardiac resynchronization therapy-defibrillator (CRT-D) implants for
primary prevention indications. ACC/AHA  American College of Cardiology/
American Heart Association; EF  ejection fraction; ICD  implantable cardiac-
defibrillator; NYHA  New York Heart Association; VT  ventricular tachycardia.oftware (SAS Institute, Cary, North Carolina).
M
besults
he characteristics of the 45,392 patients who underwent a
rst-time implantation of a CRT-D who were identified for
his study are shown in Table 1. The study population was
aseline Demographic and Admissionharacteristics Stratified by CRT Guideline AdherenceTable 1 Baseline Demographic and AdmissionCharacteristics Stratified by CRT Guideline Adherence
Characteristic
On-Label
(n  34,655)
Off-Label
(n  10,737) p Value
Age, yrs 69.8 11.2 67.9 12.3 0.001
Female 11,243 (32.4) 3,036 (28.3) 0.001
Race 0.001
White and non-Hispanic 27,733 (80.0) 8,364 (77.9)
Black and non-Hispanic 4,129 (11.9) 1,341 (12.5)
Hispanic 1,875 (5.4) 680 (6.3)
Other 918 (2.7) 352 (3.3)
Insurance payer 0.001
Government: Medicare 25,422 (73.4) 7,351 (68.5)
Government: Medicaid 1,318 (3.8) 404 (3.8)
Government: Other 279 (0.8) 108 (1.0)
Commercial 4,919 (14.2) 1,843 (17.2)
HMO 2,075 (6.0) 772 (7.2)
Other 642 (1.9) 259 (2.4)
Reason for hospitalization 0.001
Admitted for CRT placement 23,781 (68.6) 7,373 (68.7)
Hospitalized, cardiac 6,796 (19.6) 1,736 (16.2)
Hospitalized, noncardiac 3,389 (9.8) 1,361 (12.7)
Missing or unknown 689 (2.0) 267 (2.5)
Comorbidities
Family history of sudden death 1,173 (3.4) 384 (3.6) 0.341
Atrial fibrillation/atrial flutter 10,192 (29.4) 3,645 (34.0) 0.001
Sinus node dysfunction 7,720 (22.3) 2,586 (24.1) 0.001
Cardiac transplantation 56 (0.2) 21 (0.2) 0.455
Nonischemic dilated
cardiomyopathy
14,361 (41.4) 4,359 (40.6) 0.122
Ischemic heart disease 21,083 (60.8) 6,458 (60.2) 0.201
Previous MI 16,522 (47.7) 4,975 (46.3) 0.015
Previous CABG 11,987 (34.6) 3,573 (33.3) 0.012
Previous PCI 9,661 (27.9) 3,157 (29.4) 0.002
Previous valvular surgery 2,789 (8.1) 820 (7.6) 0.169
Cerebrovascular disease 4,873 (14.1) 1,435 (13.4) 0.068
Chronic lung disease 8,775 (25.3) 2,479 (23.1) 0.001
Diabetes mellitus 14,368 (41.5) 3,996 (37.2) 0.001
Hypertension 26,279 (75.8) 8,065 (75.1) 0.131
Renal failure on dialysis 1,273 (3.7) 420 (3.9) 0.255
Diagnostic data
EP study performed 2,262 (6.5) 956 (8.9) 0.001
Intraventricular conduction 0.001
Normal 2,367 (6.8) 3,525 (32.8)
Abnormal-LBBB 23,274 (67.2) 4,565 (42.5)
Abnormal-RBBB, bifascicular block
(RBBB  LAF, RBBB  LPF)
4,417 (12.8) 943 (8.8)
Other 4,597 (13.3) 1,704 (15.9)
BUN level 26.9 15.3 24.7 13.8 0.001
SBP, mm Hg 128.9 22.2 129.6 21.9 0.004
alues are mean  SD or n (%).
BUN  blood urea nitrogen; CABG  coronary artery bypass graft surgery; CRT  cardiac
esynchronization therapy; EP  electrophysiology; HMO  Health Maintenance Organization;
AF  left anterior fascicular; LBBB  left bundle branch block; LPF  left posterior fascicular;
I  myocardial infarction; PCI  percutaneous coronary intervention; RBBB  right bundle
ranch block; SBP  systolic blood pressure.
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August 31, 2010:766–73 Off-Label Use of CRT Defibrillatorsredominantly (69%) male and had a mean age of 69 years.
ore than 60% of the cohort had ischemic heart disease,
ith an average EF of 23%. For the cohort as a whole, 79%
ere NYHA functional class III and 8% were class IV.
ypertension, diabetes, AF or flutter, and/or prior coronary
evascularization were common coexisting conditions. The
ajority (72%) of the patients were Medicare beneficiaries.
A total of 10,737 (23.7%) of the implants did not meet
ontemporaneous consensus guideline criteria and were thus
onsidered off label (Fig. 1). This off-label pattern of use
as mostly due to device implantation in patients with a
YHA functional class below III (13.1%) and/or a QRS
uration 120 ms without a documented need for ventric-
lar pacing (12.0%). Only 1.3% of patients had an LVEF
35%. The CRT-D recipients had a QRS interval 100
s, NYHA functional class I, or LVEF 35% in 8% of
ases.
Univariate comparisons of on- versus off-label patient
haracteristics are also shown in Table 1. Men and non-
hite patients were more likely to have CRT implanted in
n off-label fashion than were women and white patients.
ff-label CRT recipients were also more likely than on-
abel patients to have a history of AF/flutter or sinus node
ysfunction. Off-label patients were slightly more likely to
ave had a previous PCI procedure or an electrophysiology
EP) study performed at the time of device implant than
n-label patients, and slightly less likely to have diabetes,
hronic lung disease, a previous myocardial infarction, or
oronary artery bypass graft surgery.
We also examined CRT guideline adherence across
ospitals and physicians (Table 2). There were statistically
ignificant but clinically modest differences in measures of
mplanter’s EP training, as well as hospital regional classi-
cations, teaching status, and ownership model. Off-label
RT-D procedures occurred with slightly higher frequency
n metropolitan areas and private hospitals, and operators of
ff-label procedures were slightly less likely to be board
ertified in EP.
The results of our multivariable analysis are shown in
able 3. Factors associated with increased odds of off-label
mplantation included hospitalization for noncardiac rea-
ons compared with hospitalization for the procedure,
istory of previous PCI, the performance of an EP study at
he time of device implantation, and higher systolic blood
ressure. Of all variables assessed, a history of AF/flutter
as most strongly associated with increased odds of off-label
RT-D use (odds ratio: 1.36, 95% confidence interval: 1.29
o 1.43, p  0.001). Factors significantly associated with a
ower adjusted odds of off-label implantation included older
ge, female sex, nonischemic cardiomyopathy, diabetes, and
igher BUN levels. Of note, physician training and insur-
nce payer did show weak statistical associations with
uideline adherence. Specifically, surgeons had higher ad-
usted odds (odds ratio: 1.43, 95% confidence interval: 1.16
o 1.76) of off-label utilization compared with physicians
oard-certified in EP, while patients with commercial Nnsurance had slightly higher odds of off-label implant than
atients with Medicare, and Medicaid patients slightly
ower odds. Hospital characteristics such as ownership or
eaching status did not correlate with the likelihood of
ff-label use in multivariate analysis.
In contrast to our hypotheses, we did not find that
atients receiving CRT-D devices in off-label fashion for 1
articular reason tended to have greater degrees of abnor-
ality in other implant criteria. For example, patients with
QRS duration of 120 ms or an LVEF 35% were
lightly less likely to have NYHA functional class III or IV
han were patients with a QRS duration of 120 ms (82%
s. 88%) or an LVEF 35% (73% vs. 87%), and CRT-D
ecipients with NYHA functional class I to II had a slightly
ower likelihood of baseline left bundle branch block than
hysician/Hospital Characteristicstratified by CRT Guideline AdherenceTable 2 Physician/Hospital CharacteristicsStratified by CRT Guideline Adherence
Characteristic
On-Label
(n  34,655)
Off-Label
(n  10,737) p Value
EP operator training level 0.001
Board-certified EP 25,610 (78.3) 7,748 (76.0)
EP fellowship only 2,088 (6.4) 733 (7.2)
Surgery boards 493 (1.5) 202 (2.0)
Pediatric cardiology boards 13 (0.04) 8 (0.08)
HRS guidelines 2,720 (8.3) 892 (8.8)
None of the above 1,791 (5.5) 616 (6.0)
Hospital characteristics
Owner 0.001
Public 2,793 (8.1) 904 (8.5)
Not-for-profit 26,748 (78.0) 8,091 (75.9)
Private 4,754 (13.9) 1,663 (15.6)
Core-based statistical area 0.001
Division 7,837 (22.9) 2,671 (25.1)
Metro 25,103 (73.2) 7,605 (71.4)
Micro 1,168 (3.4) 342 (3.2)
Rural 187 (0.6) 40 (0.4)
Teaching status 0.979
COTH 10,509 (30.6) 3,257 (30.6)
Teaching 8,392 (24.5) 2,617 (24.6)
Other 15,394 (44.9) 4,784 (44.9)
Cardiac facility 0.019
CABG 28,991 (84.5) 9,110 (85.5)
CATH 1,400 (4.1) 378 (3.6)
Other 3,904 (11.4) 1,170 (11.0)
Region 0.001
Associated area 44 (0.1) 21 (0.2)
New England 1,276 (3.7) 412 (3.9)
Middle Atlantic 4,782 (13.9) 1,314 (12.3)
South Atlantic 7,488 (21.8) 2,651 (24.9)
East North Central 6,249 (18.2) 1,847 (17.3)
East South Central 2,821 (8.2) 666 (6.3)
West North Central 3,033 (8.8) 847 (8.0)
West South Central 3,872 (11.3) 1,333 (12.5)
Mountain 1,553 (4.5) 475 (4.5)
Pacific 3,177 (9.3) 1,092 (10.3)
ATH  cardiac catheterization laboratory; COTH  member of Council of Teaching Hospitals;
RS  Heart Rhythm Society; other abbreviations as in Table 1.YHA functional class III or IV patients (Table 4).
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Off-Label Use of CRT Defibrillators August 31, 2010:766–73There was no evidence of either rising or declining
roportion of off-label implants over time, with the propor-
ion of procedures defined as off-label remaining between
2% and 25% for each quarter we assessed (p for trend 
.30) (Fig. 2). Although the total number of CRT-D
mplants appeared to increase substantially after the first
uarter of 2006, it should be noted that this was the first
uarter of data entry into NCDR’s ICD Registry; thus,
nitial procedure volumes were likely underestimated.
iscussion
nvestigating the use of CRT in clinical practice using a
arge, national patient registry, our study had 4 main
actors Associated With Off-Label CRTmplantation (Hierarchical Logistic Regression Model)Table 3 Factors Associated With Off-Label CRTImplantation (Hierarchical Logistic Regression Model)
Variable Odds Ratio (95% CI) p Value
Age, per decade 0.85 (0.83–0.87) 0.001
Female 0.86 (0.82–0.91) 0.001
Diabetes mellitus 0.86 (0.82–0.90) 0.001
Atrial fibrillation/atrial flutter 1.36 (1.29–1.43) 0.001
Nonischemic dilated cardiomyopathy 0.85 (0.78–0.92) 0.001
Ischemic heart disease 0.89 (0.82–0.97) 0.01
BUN, per 10 mg/dl 0.93 (0.91–0.94) 0.001
SBP, per 10 mm Hg 1.03 (1.02–1.04) 0.001
Previous PCI 1.11 (1.05–1.18) 0.001
Previous valve surgery 0.89 (0.82–0.97) 0.01
Chronic lung disease 0.93 (0.88–0.98) 0.005
EP study performed 1.31 (1.19–1.43) 0.001
EP operator training*
EP fellowship 1.01 (0.90–1.14) 0.84
Surgery boards 1.43 (1.16–1.76) 0.001
Pediatric cardiology boards 1.06 (0.36–3.16) 0.91
HRS guidelines 1.10 (0.98–1.22) 0.11
None of the above 1.27 (1.11–1.45) 0.001
Insurance payer†
Government: Medicaid 0.87 (0.77–0.99) 0.03
Government: other 1.07 (0.85–1.36) 0.55
Commercial 1.09 (1.02–1.17) 0.01
HMO 1.09 (0.99–1.20) 0.08
Other 1.06 (0.90–1.24) 0.47
Hospitalization reason‡
Cardiac 0.82 (0.77–0.87) 0.001
Noncardiac 1.18 (1.09–1.27) 0.001
Reference category: board-certified EP. †Reference category: Medicare. ‡Reference category:
dmitted for procedure.
CI  confidence interval; other abbreviations as in Tables 1 and 2.
omparison of Clinical Parameters in Subgroups Stratified by IndivTable 4 Comparison of Clinical Parameters in Subgroups Strati
QRS Duration
<120 ms
(n  5,840)
>120 ms
(n  39,552)
Mean QRS duration, ms (SD) — —
Mean LVEF, % (SD) 23.8 (7.6) 23.2 (6.8)
NYHA functional class III or IV, n (%) 4,761 (81.5) 34,672 (87.7)
Left bundle branch block, n (%) 1,170 (20.0) 26,669 (67.4)VEF  left ventricular ejection fraction; NYHA  New York Heart Association.ndings. First, nearly 1 in 4 patients in contemporary
ommunity practice who received new CRT placement
rom 2006 to 2008 did so outside current clinical guideline
ecommendations. Second, this pattern of device utilization
as not easily explained by geographic, hospital, or physi-
ian factors, although weak associations with insurance
tatus and physician training were observed. Third, guide-
ine nonadherence for CRT implantation varied by patient
ex, age, history of AF, comorbid conditions, and a prior
attern of invasive cardiac interventions. Last, there was no
ignificant trend toward increasing or decreasing adherence
o guideline-based indications over the time period of this
tudy.
A number of randomized clinical trials have established
hat CRT improves ventricular function and symptom
tatus while reducing hospitalizations and mortality in a
ajority of carefully selected heart failure patients (1–4).
nalysis of the ICD Registry, however, shows that in
Figure 2 Time Trends for CRT-D Implants
in NCDR ICD Registry
Time trends for cardiac resynchronization therapy-defibrillator (CRT-D) implants
in the National Cardiovascular Data Registry (NCDR) Implantable Cardiac Defi-
brillator (ICD) Registry from January 2006 through June 2008. In each quarter
examined, the proportion of implants defined as off-label (blue bars) ranged
from 27% to 29%. Note that the appearance of growth in overall procedural
volume from the first quarter to the second quarter of 2006 is likely due to
incomplete data for Q1, 2006, the first quarter of data entry into the registry,
rather than actual changes in procedure rates. The orange bars indicate on-la-
bel implants.
Guideline Criteriay Individual Guideline Criteria
LVEF NYHA Functional Class
>35%
(n  582)
<35%
(n  44,810)
I–II
(n  6,081)
III–IV
(n  40,117)
137.4 (28.7) 145.7 (26.9) 143.4 (28.9) 145.9 (26.6)
— — 24.5 (7.2) 23.1 (6.9)
426 (73.2) 39,007 (87.0) — —
269 (46.2) 27,570 (61.5) 3,435 (57.6) 24,404 (61.9)idualfied b
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August 31, 2010:766–73 Off-Label Use of CRT Defibrillatorsoutine clinical practice, nearly 1 in 4 CRT-D devices were
mplanted outside current consensus guidelines, which are
ased mainly on the entry criteria of clinical trials demon-
trating the efficacy of CRT devices. Even allowing for
vidence from trials published after the timeframe of our
nalysis, many of these patients would not be expected to
erive the same benefits from CRT as patients identified in
revious randomized trials. CRT implantation is an invasive
rocedure associated with important rates of short- and
ong-term complications, and is more expensive than stan-
ard ICD implantation. Until the effectiveness, cost effec-
iveness, and safety of CRT in larger populations are
emonstrated, the wisdom of widespread off-label CRT
tilization should be carefully questioned.
While it is relatively straightforward to classify CRT-D
rocedures in the Registry as on- or off-label, we would
aution against equating off-label care with inappropriate
are. For example, our study identified AF/flutter as a factor
ssociated with increased likelihood of off-label device
sage. This could be because implanting physicians expect
hat some patients with AF/flutter and a normal QRS
uration who are appropriate ICD candidates will pace
requently in the ventricle because of pauses and bradycardia
e.g., with intensification of beta-blocker therapy). It may be
easonable to add a left ventricle pacing lead in these cases,
iven the known deleterious effects of right ventricle pacing
n ICD patients (13). Alternatively, CRT-D devices may be
hosen in conjunction with ablation of the AV junction as a
trategy to both treat heart failure and symptoms of AF
14–16). Although such procedures are off-label, we would
ot necessarily consider them inappropriate.
In addition, guidelines can and do evolve as technologies
re studied for new indications, and portions of the clinical
ommunity may change their practices in advance of clinical
rial evidence and guideline revision. For example, both the
ADIT-CRT (Multicenter Automatic Defibrillator Im-
lantation Trial With Cardiac Resynchronization Therapy)
9) and longer-term follow-up data from the REVERSE
Resynchronization Reverses Remodeling in Systolic Left
entricular Dysfunction) study (17) found that CRT ther-
py was associated with significant reductions in heart
ailure events (albeit not mortality) and improvements in
ardiac structure and function (9,18) when compared with
tandard ICDs in patients with reduced EF, prolonged
RS duration, and only NYHA functional class I or II
eart failure. As our study period preceded the publication
f these results, the appropriateness of CRT-D implants in
YHA functional class I and II patients during this time
rame is uncertain. While we understand clinicians’ desire to
rovide patients the “benefit of the doubt,” particularly in
orderline cases, had MADIT-CRT been a negative trial,
e might in hindsight have concluded that these procedures
ook on unjustified risk and expense.
Off-label use of medical technology is perhaps most
roblematic in cases where the expectation of benefit is low,
r when there is actually evidence that benefit is absent. We hound that a low proportion of CRT-D devices (1.3%) were
mplanted in patients with an LVEF35%, but that a fairly
igh proportion—12.0%—had a QRS duration 120 ms
nd no documented need for ventricular pacing (5.6% had a
RS duration 100 ms). Although the use of CRT in
atients with echocardiographic evidence of dyssynchrony
ven with a narrow QRS showed initial promise in nonran-
omized studies (19–21), the RETHINQ (Cardiac Resyn-
hronization Therapy in Patients With Heart Failure and
arrow QRS) trial (22) reported a lack of benefit from
RT in patients with a QRS of 120 ms, and the
ROSPECT study (23) raised serious doubts about the
eproducibility of echocardiographic measures of dyssyn-
hrony as a means of selecting patients for CRT. Despite
hese negative findings, the implantation of CRT-D devices
n patients with narrow QRS complexes appears to have
ontinued.
We find the high frequency of off-label CRT utilization
bserved in our study potentially concerning for several
easons. First, although major complication rates from CRT
rocedures are acceptably low in experienced hands, a
revious analysis from the ICD Registry has confirmed that
he probability of an implant complication is more than
wice as high with a CRT-D procedure than with a
ingle-chamber implant (24). Similar results were recently
eported from an Ontario registry (25). Implantation of a
RT-D system is also at least $6,000 to $10,000 more
xpensive than implantation of a single-chamber system.
inally, CRT is well known to have a nonresponse rate of up
o 30% even for guideline-recommended indications. For all
f these reasons, implantation of CRT-D systems in the
ontext of a low probability of incremental clinical benefit
ay increase risk for patients, costs for the health care
ystem, and erode the cost-effectiveness of the therapy. In
ur opinion, the resources expended in at least some of these
ff-label procedures would be better directed at addressing
he documented underuse of CRT in more appropriate
andidates (10).
Two previous studies examined the patterns of CRT-D
sage and reported on factors associated with off-label use.
sing data from the Get With The Guidelines-Heart
ailure (GWTG-HF) program, Piccini et al. (10) docu-
ented that 9.6% of patients receiving new CRT-Ds had an
VEF 35%, a figure far higher than what we observed in
he ICD Registry. These results could have differed for
everal reasons: the studies covered slightly different time-
rames, the GWTG study had far fewer new CRT-D
ecipients (n  811) than our study, and the GWTG-HF
rogram only involves patients hospitalized for a heart
ailure exacerbation at selected centers. Whereas Piccini et
l. (10) also demonstrated regional and hospital variation in
he use of CRT technology for potentially appropriate
andidates, we did not find significant associations with
ff-label CRT-D use and either geographical region or
ospital characteristics.
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Off-Label Use of CRT Defibrillators August 31, 2010:766–73Contrary to a previous analysis of ICD Registry data (11),
ur study did not show an association between race and
RT-D therapy use outside published guidelines. An ex-
lanation for the discrepancy between these 2 studies is also
nclear. Our study had a slightly more recent time frame
2006 to 2008 vs. 2005 to 2007), differed in the definition of
ff-label device usage (by accepting AV block as on-label),
nd used different covariates in multivariate modeling. Both
he prior ICD Registry study and the GWTG study found
hat the utilization of CRT for potentially appropriate
onwhite candidates was lower than for white patients.
We found significantly reduced odds of off-label device
tilization with increasing age, female sex, diabetes, and
levated blood urea nitrogen levels. A few of these factors
ave been associated with increased risk of procedural
omplications (26) and reduced benefit with prophylactic
CD implantation (27). These associations suggest that
linicians may be less likely to extend off-label CRT-D
herapy to patients for whom the likelihood of benefit
ppears reduced and/or the risk of complications appears
ncreased.
Although we did not identify physician or hospital factors
redictive of off-label CRT-D usage, we did find increased
dds of off-label implants in patients with prior PCI or EP
tudy. Health services literature that has explored the factors
ssociated with medical technology overuse has found a
irect relationship with the availability of supply (28). The
ssociation between off-label CRT-D implantation and a
istory of other invasive cardiac procedures factors may,
herefore, reflect physician or hospital characteristics not
aptured in the variables we assessed. It is also possible that
nformation obtained during an EP study (e.g., abnormal-
ties in AV conduction) may influence the choice of device
n some cases.
In multivariate analysis, we did find a weak association
etween guideline adherence and insurer, with Medicaid
atients slightly less likely to receive off-label CRT, and
ommercial insurance slightly more likely, compared with
edicare. All other things being equal, the patient’s insur-
nce may therefore be a minor consideration when these
ecisions are made. We also observed somewhat stronger
ssociations between guideline adherence and physician
raining, indicating that implanters without EP training of
ome kind (including surgeons) may be more likely to use a
RT-D in an off-label fashion. A previous registry analysis
ound a higher rate of early complications when ICDs were
mplanted by surgeons (24).
tudy limitations. While the registry includes a substantial
umber of data elements, it may still lack sufficient clinical
etail to judge the appropriateness of device utilization in
any cases. Another limitation common to all ICD registry
nalyses is that the registry has no systemic approach to
uditing the data. Although many consistency checks were
nstituted in the data collection process, the overall accuracy
f the data is not known. Additionally, the registry does not
asily facilitate interpretation of a patient’s drug regimen, ast lacks complete information on drug doses or intolerance,
id not specifically include aldosterone antagonists, and is
imited to discharge medications after device implantation.
ith recently published data indicating substantial under-
tilization of beta-blockers before ICD implantation (29),
e would hypothesize that incorporation of an “optimal
edical therapy” criterion into our definition of off-label
reatment would only increase the prevalence of guideline
onadherence. Finally, the large sample sizes involved in
nalyses like this one increase the potential for both type I
false positive) statistical error and the identification of true
ssociations that are clinically unimportant.
onclusions
rom the ICD Registry experience, the use of cardiac
esynchronization defibrillators in clinical practice is fre-
uently noncompliant with evidence-based consensus
uidelines. Nearly 1 in 4 devices placed from 2006 to 2008
id not conform to contemporaneous guidelines, and many
f these might presently be considered inappropriate even
hen allowing for potential future guideline changes. This
attern of practice is not easily explained by geographic,
ospital, or physician factors. Implantation of a CRT-D (vs.
tandard ICD) in patients with a low probability of incre-
ental benefit should be discouraged.
eprint requests and correspondence: Dr. Matthew R. Reyn-
lds, Beth Israel Deaconess Medical Center, 185 Pilgrim Road,
oston, Massachusetts 02217. E-mail: mreynold@bidmc.
arvard.edu.
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